(Q28242989)

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Mitiglinide: KAD 1229, S 21403

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Beta-cell response during a meal test: a comparative study of incremental doses of repaglinide in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Mealtime glucose regulation by nateglinide in type-2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Beta-cell insulin secretory response to oral hypoglycemic agents is blunted in humans in vivo during moderate hypoglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Repaglinide versus nateglinide monotherapy: a randomized, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Efficacy and safety of once daily gliclazide (20 mg/day) compared with nateglinide

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Repaglinide/bedtime NPH insulin is comparable to twice-daily NPH insulin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Nateglinide alone or with metformin safely improves glycaemia to target in patients up to an age of 84.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Repaglinide acutely amplifies pulsatile insulin secretion by augmentation of burst mass with no effect on burst frequency.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Sulfonylurea induced beta-cell apoptosis in cultured human islets

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Repaglinide administration improves brachial reactivity in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Restoration of early insulin secretion after a meal in type 2 diabetes: effects on lipid and glucose metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus--a randomized study using positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970257-4

7 January 2021

10.1016/S1262-3636(07)70257-4

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

16735959

1 reference

Consolidated OpenCitations Corpus – April 2017